BR112023015976A2 - Compostos de anel aromático de pirimidina - Google Patents

Compostos de anel aromático de pirimidina

Info

Publication number
BR112023015976A2
BR112023015976A2 BR112023015976A BR112023015976A BR112023015976A2 BR 112023015976 A2 BR112023015976 A2 BR 112023015976A2 BR 112023015976 A BR112023015976 A BR 112023015976A BR 112023015976 A BR112023015976 A BR 112023015976A BR 112023015976 A2 BR112023015976 A2 BR 112023015976A2
Authority
BR
Brazil
Prior art keywords
aromatic ring
ring compounds
pyrimidine
pyrimidine aromatic
compounds
Prior art date
Application number
BR112023015976A
Other languages
English (en)
Inventor
Kaijun Geng
Shuhui Chen
Wentao Wu
Yang Zhang
Yangyang Xu
Zhixiang Li
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of BR112023015976A2 publication Critical patent/BR112023015976A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

compostos de anel aromático de pirimidina. são fornecidos compostos de anel aromático de pirimidina. é especificamente fornecido um composto conforme representado pela fórmula (ii) ou um sal farmaceuticamente aceitável do mesmo.
BR112023015976A 2021-02-09 2022-02-09 Compostos de anel aromático de pirimidina BR112023015976A2 (pt)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN202110182357 2021-02-09
CN202110251656 2021-03-08
CN202110379326 2021-04-08
CN202110485837 2021-04-30
CN202110825879 2021-07-21
CN202110975205 2021-08-24
CN202111136266 2021-09-27
CN202111283561 2021-11-01
CN202210072243 2022-01-21
CN202210113080 2022-01-29
PCT/CN2022/075732 WO2022171147A1 (zh) 2021-02-09 2022-02-09 嘧啶并芳香环类化合物

Publications (1)

Publication Number Publication Date
BR112023015976A2 true BR112023015976A2 (pt) 2023-12-12

Family

ID=82837454

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023015976A BR112023015976A2 (pt) 2021-02-09 2022-02-09 Compostos de anel aromático de pirimidina

Country Status (9)

Country Link
EP (1) EP4293027A1 (pt)
JP (1) JP2024505594A (pt)
KR (1) KR20230136636A (pt)
CN (1) CN116888128A (pt)
AU (1) AU2022219124A1 (pt)
BR (1) BR112023015976A2 (pt)
CA (1) CA3207800A1 (pt)
IL (1) IL305033A (pt)
WO (1) WO2022171147A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115141215B (zh) * 2021-03-30 2023-09-15 上海德琪医药科技有限公司 Kras g12d蛋白抑制剂和其用途
WO2023039240A1 (en) * 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023061294A1 (zh) * 2021-10-13 2023-04-20 再鼎医药(上海)有限公司 含氮杂环类衍生物调节剂、其制备方法及应用
WO2023072188A1 (zh) * 2021-10-29 2023-05-04 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
WO2023138583A1 (zh) * 2022-01-21 2023-07-27 上海湃隆生物科技有限公司 杂环类化合物、药物组合物及其应用
WO2023138662A1 (zh) * 2022-01-21 2023-07-27 南京明德新药研发有限公司 苯并嘧啶类化合物及其应用
WO2023152255A1 (en) * 2022-02-10 2023-08-17 Bayer Aktiengesellschaft Fused pyrimidines as kras inhibitors
WO2024008179A1 (en) * 2022-07-07 2024-01-11 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
CN117263959A (zh) * 2022-10-24 2023-12-22 药雅科技(上海)有限公司 芳香类kras突变蛋白抑制剂的制备及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190186A1 (ar) * 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
CA3120383A1 (en) * 2018-11-29 2020-06-04 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
WO2020177629A1 (zh) * 2019-03-01 2020-09-10 劲方医药科技(上海)有限公司 螺环取代的嘧啶并环类化合物，其制法与医药上的用途
CN112110918B (zh) * 2019-06-21 2023-08-22 劲方医药科技(上海)有限公司 螺环取代的嘧啶并环类化合物，其制法与医药上的用途
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
CN115836055A (zh) * 2020-06-30 2023-03-21 益方生物科技(上海)股份有限公司 喹唑啉化合物、其制备方法和用途
JP2023540270A (ja) * 2020-08-28 2023-09-22 カムクワット バイオサイエンシーズ インコーポレイテッド 複素環式化合物およびその使用
WO2022061251A1 (en) * 2020-09-18 2022-03-24 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
CN114031562A (zh) * 2021-10-31 2022-02-11 南京碳硅人工智能生物医药技术研究院有限公司 一种具有抗肿瘤的吡啶衍生物的工艺优化

Also Published As

Publication number Publication date
AU2022219124A1 (en) 2023-08-31
CA3207800A1 (en) 2022-08-18
KR20230136636A (ko) 2023-09-26
JP2024505594A (ja) 2024-02-06
WO2022171147A1 (zh) 2022-08-18
EP4293027A1 (en) 2023-12-20
CN116888128A (zh) 2023-10-13
IL305033A (en) 2023-10-01

Similar Documents

Publication Publication Date Title
BR112023015976A2 (pt) Compostos de anel aromático de pirimidina
CR20210032A (es) Compuestos
EA201892300A1 (ru) Макроциклические ингибиторы mcl1 для лечения рака
BR112022018140A2 (pt) Compostos pirimidoheterocíclicos e aplicação dos mesmos
CL2022001731A1 (es) Inhibidores de egfr.
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
BR112021022105A2 (pt) Inibidores de cdk
MA40302B1 (fr) Dérivés de carbazole
EA201290632A1 (ru) Производные бетулина
EA201170617A1 (ru) Пиразолиламинопиридины в качестве ингибиторов fak
MX2021000348A (es) 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo.
MX2018001991A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
BR112022006202A2 (pt) Compostos heterocíclicos de arila como bloqueadores de canal do agitador de potássio kv1,3
MA50093B1 (fr) Composé pentacyclique
MX2021012105A (es) Compuestos de pirrol.
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
BR112022006242A2 (pt) Compostos aromáticos de arilmetileno como bloqueadores de canal do agitador de potássio kv1,3
CO2022004391A2 (es) Derivados de 5-oxa-2–azaespiro[3.4]octano como agonistas de m4
BR112023001962A2 (pt) Forma sólida de composto
BR112022006507A2 (pt) Compostos heterocíclicos de arilmetileno como bloqueadores de canais de agitador de potássio kv1.3
MX2021014629A (es) Compuestos tetraciclicos como inhibidores de cdc7.
BR112022006250A2 (pt) Compostos heterobicíclicos de arila como bloqueadores de canal de agitador de potássio kv1.3